Pegunigalsidase alfa Alternatives Compared
| Pegunigalsidase alfa | Fabrazyme (agalsidase beta) | Galafold (migalastat) |
|
|---|
| Pegunigalsidase alfa | Fabrazyme (agalsidase beta) | Galafold (migalastat) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Fabry Disease. Pegunigalsidase alfa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Fabry Disease. Fabrazyme may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Fabry Disease. Galafold may also be used for purposes not listed in this medication guide. |
Related suggestions Fabry Disease
|
|||||||||||||||
| More about Pegunigalsidase alfa | More about Fabrazyme (agalsidase beta) | More about Galafold (migalastat) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Pegunigalsidase alfa has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Pegunigalsidase alfa side effects |
View all Fabrazyme side effects |
View all Galafold side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Fabrazyme prices |
View all Galafold prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Elfabrio |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
121 hours |
1.7 hours |
5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 6 drugs are known to interact with Pegunigalsidase alfa:
|
A total of 5 drugs are known to interact with Fabrazyme:
|
A total of 1 drugs are known to interact with Galafold:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
April 24, 2003 |
August 10, 2018 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.